After decades of being woefully under-diagnosed and all but ignored by the biotech and pharma industry, recent advances in understanding its complex etiology could be opening the way to new treatments for endometriosis. Impetus is coming from (modest) increases in funding for basic research, such as the Biden administration’s $200 million for women’s health research and NIH grants under an ‘Advancing cures and therapies and ending endometriosis diagnostic delays’ call announced in March of this year. Read More
Immunotherapy-focused biotech company LTZ Therapetics Inc. raised $20 million in a series A round that will advance development of its myeloid engager pipeline to treat cancer and autoimmune diseases. Proceeds from the funds will accelerate development of lead asset LTZ-301, which is expected to enter the clinic in early 2025, LTZ founder and CEO Robert Li told BioWorld. Read More
The interaction between the transcriptional co-repressor runt-related transcription factor 1 translocation partner 1 (Runx1t1) and MYCN, a member of the MYC proto-oncogene family, plays a crucial role in the development of neuroblastoma, according to a study led by the Children's Cancer Institute at Lowy Cancer Centre, UNSW Sydney. Read More
Researchers from Contineum Therapeutics Inc. have presented preclinical data for the novel brain penetrant lysophosphatidic acid receptor 1 (LPAR1) antagonist, PIPE-791, being evaluated in models of neuropathic pain. Read More
Researchers from Sun Pharmaceutical Advanced Research Co. Ltd. and the University of California have synthesized drug conjugates consisting of PSMA targeting moiety covalently linked to therapeutic and/or cytotoxic agent reported to be useful for the treatment of cancer. Read More
Tr1x Inc. has announced that the FDA has cleared its IND application for its engineered Tr1 Treg cell therapy TRX-103 for treatment-refractory Crohn’s disease. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Actio Biosciences Inc.’s ABS-0871 has received both orphan drug designation and rare pediatric disease designation from the FDA. ABS-0871 is in preclinical development for the treatment of Charcot-Marie-Tooth disease subtype 2C (CMT2C). Read More
The U.S. Department of Health and Human Services has patented HIV integrase inhibitors reported to be useful for the treatment of HIV infections. Read More
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others. Read More
Researchers from Alzecure Pharma AB presented preclinical data for ACD-137, a negative allosteric modulator (NAM) of tropomyosin receptor kinase A (TrkA), being developed for the treatment of pain. Read More
Mitsubishi Tanabe Pharma Corp. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase (CRBN) binding moiety coupled to disease-associated protein targeting moiety through a linker reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune disease, neurodegeneration and genetic disorders. Read More
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from the Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province have gained new insights into the role of histamine receptors in fear memories. Read More
